News

Filter

Merck KGaA returns rights to IMO-2055 in oncology to Idera Pharma

01-12-2011

USA-based Idera Pharmaceuticals (Nasdaq: IDRA) revealed yesterday that it has regained global rights…

Idera PharmaceuticalsLicensingMerck KGaAOncologyPharmaceuticalResearch

CV events halt Sanofi Multaq trial; Merck KGaA drops Idera cancer drug on safety concerns

08-07-2011

In two clinical disappointments announced yesterday, French drug major Sanofi (Euronext: SAN) and Germany’s…

Cardio-vascularIdera PharmaceuticalsMerck KGaAMultaqOncologyPharmaceuticalResearchSanofi

COMPANY SPOTLIGHT

Menarini

Back to top